Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph not_applicable
2
67%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

unknown1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

unknown133%
recruiting133%
terminated133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingnot_applicable

Long-term COVID and Rehabilitation

NCT05373043
terminatedphase_1

MitoQ for Fatigue in Multiple Sclerosis

NCT03166800
unknownnot_applicable

The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients

NCT05146843

Clinical Trials (3)

Showing 3 of 3 trials
NCT05373043Not Applicable

Long-term COVID and Rehabilitation

Recruiting
NCT03166800Phase 1

MitoQ for Fatigue in Multiple Sclerosis

Terminated
NCT05146843Not Applicable

The Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer Patients

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
3